Global Pegfilgrastim Biosimilar Market Research Report 2023

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

The global Pegfilgrastim Biosimilar market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.

North American market for Pegfilgrastim Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Pegfilgrastim Biosimilar is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global manufacturers of Pegfilgrastim Biosimilar include Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy’s Laboratories, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Pegfilgrastim Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pegfilgrastim Biosimilar.

The Pegfilgrastim Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pegfilgrastim Biosimilar market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Pegfilgrastim Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

1.1 Product Overview and Scope of Pegfilgrastim Biosimilar

1.2 Pegfilgrastim Biosimilar Segment by Type

1.2.1 Global Pegfilgrastim Biosimilar Market Value Comparison by Type (2023-2029)

1.2.2 Chemotherapy Treatment

1.2.3 Transplantation

1.3 Pegfilgrastim Biosimilar Segment by Application

1.3.1 Global Pegfilgrastim Biosimilar Market Value by Application: (2023-2029)

1.3.2 Hospital Pharmacies

1.3.3 Mail-Order Pharmacies

1.3.4 Retail Pharmacies

1.4 Global Pegfilgrastim Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Pegfilgrastim Biosimilar Revenue 2018-2029

1.4.2 Global Pegfilgrastim Biosimilar Sales 2018-2029

1.4.3 Global Pegfilgrastim Biosimilar Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2.1 Global Pegfilgrastim Biosimilar Sales Market Share by Manufacturers (2018-2023)

2.2 Global Pegfilgrastim Biosimilar Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Pegfilgrastim Biosimilar Average Price by Manufacturers (2018-2023)

2.4 Global Pegfilgrastim Biosimilar Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Pegfilgrastim Biosimilar, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Pegfilgrastim Biosimilar, Product Type & Application

2.7 Pegfilgrastim Biosimilar Market Competitive Situation and Trends

2.7.1 Pegfilgrastim Biosimilar Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Pegfilgrastim Biosimilar Players Market Share by Revenue

2.7.3 Global Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Pegfilgrastim Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Pegfilgrastim Biosimilar Global Pegfilgrastim Biosimilar Sales by Region: 2018-2029

3.2.1 Global Pegfilgrastim Biosimilar Sales by Region: 2018-2023

3.2.2 Global Pegfilgrastim Biosimilar Sales by Region: 2024-2029

3.3 Global Pegfilgrastim Biosimilar Global Pegfilgrastim Biosimilar Revenue by Region: 2018-2029

3.3.1 Global Pegfilgrastim Biosimilar Revenue by Region: 2018-2023

3.3.2 Global Pegfilgrastim Biosimilar Revenue by Region: 2024-2029

3.4 North America Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.4.1 North America Pegfilgrastim Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Pegfilgrastim Biosimilar Sales by Country (2018-2029)

3.4.3 North America Pegfilgrastim Biosimilar Revenue by Country (2018-2029)

3.4.4 United States

3.4.5 Canada

3.5 Europe Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.5.1 Europe Pegfilgrastim Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Pegfilgrastim Biosimilar Sales by Country (2018-2029)

3.5.3 Europe Pegfilgrastim Biosimilar Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.6.1 Asia Pacific Pegfilgrastim Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Pegfilgrastim Biosimilar Sales by Country (2018-2029)

3.6.3 Asia Pacific Pegfilgrastim Biosimilar Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Pegfilgrastim Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Pegfilgrastim Biosimilar Sales by Country (2018-2029)

3.7.3 Latin America Pegfilgrastim Biosimilar Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Pegfilgrastim Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Pegfilgrastim Biosimilar Sales by Country (2018-2029)

3.8.3 Middle East and Africa Pegfilgrastim Biosimilar Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Pegfilgrastim Biosimilar Sales by Type (2018-2029)

4.1.1 Global Pegfilgrastim Biosimilar Sales by Type (2018-2023)

4.1.2 Global Pegfilgrastim Biosimilar Sales by Type (2024-2029)

4.1.3 Global Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2029)

4.2 Global Pegfilgrastim Biosimilar Revenue by Type (2018-2029)

4.2.1 Global Pegfilgrastim Biosimilar Revenue by Type (2018-2023)

4.2.2 Global Pegfilgrastim Biosimilar Revenue by Type (2024-2029)

4.2.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2018-2029)

4.3 Global Pegfilgrastim Biosimilar Price by Type (2018-2029)

5.1 Global Pegfilgrastim Biosimilar Sales by Application (2018-2029)

5.1.1 Global Pegfilgrastim Biosimilar Sales by Application (2018-2023)

5.1.2 Global Pegfilgrastim Biosimilar Sales by Application (2024-2029)

5.1.3 Global Pegfilgrastim Biosimilar Sales Market Share by Application (2018-2029)

5.2 Global Pegfilgrastim Biosimilar Revenue by Application (2018-2029)

5.2.1 Global Pegfilgrastim Biosimilar Revenue by Application (2018-2023)

5.2.2 Global Pegfilgrastim Biosimilar Revenue by Application (2024-2029)

5.2.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2018-2029)

5.3 Global Pegfilgrastim Biosimilar Price by Application (2018-2029)

6.1 Novartis

6.1.1 Novartis Corporation Information

6.1.2 Novartis Description and Business Overview

6.1.3 Novartis Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.1.4 Novartis Pegfilgrastim Biosimilar Product Portfolio

6.1.5 Novartis Recent Developments/Updates

6.2 Mylan

6.2.1 Mylan Corporation Information

6.2.2 Mylan Description and Business Overview

6.2.3 Mylan Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.2.4 Mylan Pegfilgrastim Biosimilar Product Portfolio

6.2.5 Mylan Recent Developments/Updates

6.3 Coherus BioSciences

6.3.1 Coherus BioSciences Corporation Information

6.3.2 Coherus BioSciences Description and Business Overview

6.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Coherus BioSciences Pegfilgrastim Biosimilar Product Portfolio

6.3.5 Coherus BioSciences Recent Developments/Updates

6.4 Mundipharma International

6.4.1 Mundipharma International Corporation Information

6.4.2 Mundipharma International Description and Business Overview

6.4.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Mundipharma International Pegfilgrastim Biosimilar Product Portfolio

6.4.5 Mundipharma International Recent Developments/Updates

6.5 Biocon

6.5.1 Biocon Corporation Information

6.5.2 Biocon Description and Business Overview

6.5.3 Biocon Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.5.4 Biocon Pegfilgrastim Biosimilar Product Portfolio

6.5.5 Biocon Recent Developments/Updates

6.6 Intas Pharmaceuticals

6.6.1 Intas Pharmaceuticals Corporation Information

6.6.2 Intas Pharmaceuticals Description and Business Overview

6.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.6.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Portfolio

6.6.5 Intas Pharmaceuticals Recent Developments/Updates

6.7 Pfizer

6.6.1 Pfizer Corporation Information

6.6.2 Pfizer Description and Business Overview

6.6.3 Pfizer Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Pfizer Pegfilgrastim Biosimilar Product Portfolio

6.7.5 Pfizer Recent Developments/Updates

6.8 Dr Reddy’s Laboratories

6.8.1 Dr Reddy’s Laboratories Corporation Information

6.8.2 Dr Reddy’s Laboratories Description and Business Overview

6.8.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.8.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Portfolio

6.8.5 Dr Reddy’s Laboratories Recent Developments/Updates

7.1 Pegfilgrastim Biosimilar Industry Chain Analysis

7.2 Pegfilgrastim Biosimilar Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Pegfilgrastim Biosimilar Production Mode & Process

7.4 Pegfilgrastim Biosimilar Sales and Marketing

7.4.1 Pegfilgrastim Biosimilar Sales Channels

7.4.2 Pegfilgrastim Biosimilar Distributors

7.5 Pegfilgrastim Biosimilar Customers

8.1 Pegfilgrastim Biosimilar Industry Trends

8.2 Pegfilgrastim Biosimilar Market Drivers

8.3 Pegfilgrastim Biosimilar Market Challenges

8.4 Pegfilgrastim Biosimilar Market Restraints

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

    Table 1. Global Pegfilgrastim Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

    Table 2. Global Pegfilgrastim Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

    Table 3. Global Pegfilgrastim Biosimilar Market Competitive Situation by Manufacturers in 2022

    Table 4. Global Pegfilgrastim Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)

    Table 5. Global Pegfilgrastim Biosimilar Sales Market Share by Manufacturers (2018-2023)

    Table 6. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)

    Table 7. Global Pegfilgrastim Biosimilar Revenue Share by Manufacturers (2018-2023)

    Table 8. Global Market Pegfilgrastim Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)

    Table 9. Global Key Players of Pegfilgrastim Biosimilar, Industry Ranking, 2021 VS 2022 VS 2023

    Table 10. Global Key Manufacturers of Pegfilgrastim Biosimilar, Manufacturing Sites & Headquarters

    Table 11. Global Key Manufacturers of Pegfilgrastim Biosimilar, Product Type & Application

    Table 12. Global Key Manufacturers of Pegfilgrastim Biosimilar, Date of Enter into This Industry

    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

    Table 14. Global Pegfilgrastim Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pegfilgrastim Biosimilar as of 2022)

    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 16. Global Pegfilgrastim Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 17. Global Pegfilgrastim Biosimilar Sales by Region (2018-2023) & (K Units)

    Table 18. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2018-2023)

    Table 19. Global Pegfilgrastim Biosimilar Sales by Region (2024-2029) & (K Units)

    Table 20. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2024-2029)

    Table 21. Global Pegfilgrastim Biosimilar Revenue by Region (2018-2023) & (US$ Million)

    Table 22. Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2018-2023)

    Table 23. Global Pegfilgrastim Biosimilar Revenue by Region (2024-2029) & (US$ Million)

    Table 24. Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2024-2029)

    Table 25. North America Pegfilgrastim Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 26. North America Pegfilgrastim Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 27. North America Pegfilgrastim Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 28. North America Pegfilgrastim Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 29. North America Pegfilgrastim Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 30. Europe Pegfilgrastim Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 31. Europe Pegfilgrastim Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 32. Europe Pegfilgrastim Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 33. Europe Pegfilgrastim Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 34. Europe Pegfilgrastim Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 35. Asia Pacific Pegfilgrastim Biosimilar Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

    Table 36. Asia Pacific Pegfilgrastim Biosimilar Sales by Region (2018-2023) & (K Units)

    Table 37. Asia Pacific Pegfilgrastim Biosimilar Sales by Region (2024-2029) & (K Units)

    Table 38. Asia Pacific Pegfilgrastim Biosimilar Revenue by Region (2018-2023) & (US$ Million)

    Table 39. Asia Pacific Pegfilgrastim Biosimilar Revenue by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Pegfilgrastim Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 41. Latin America Pegfilgrastim Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 42. Latin America Pegfilgrastim Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 43. Latin America Pegfilgrastim Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Pegfilgrastim Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 46. Middle East & Africa Pegfilgrastim Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 47. Middle East & Africa Pegfilgrastim Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 48. Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 50. Global Pegfilgrastim Biosimilar Sales (K Units) by Type (2018-2023)

    Table 51. Global Pegfilgrastim Biosimilar Sales (K Units) by Type (2024-2029)

    Table 52. Global Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2023)

    Table 53. Global Pegfilgrastim Biosimilar Sales Market Share by Type (2024-2029)

    Table 54. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Type (2018-2023)

    Table 55. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Type (2024-2029)

    Table 56. Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2018-2023)

    Table 57. Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2024-2029)

    Table 58. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Type (2018-2023)

    Table 59. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Type (2024-2029)

    Table 60. Global Pegfilgrastim Biosimilar Sales (K Units) by Application (2018-2023)

    Table 61. Global Pegfilgrastim Biosimilar Sales (K Units) by Application (2024-2029)

    Table 62. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2018-2023)

    Table 63. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2024-2029)

    Table 64. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Application (2018-2023)

    Table 65. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Application (2024-2029)

    Table 66. Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2018-2023)

    Table 67. Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2024-2029)

    Table 68. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Application (2018-2023)

    Table 69. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Application (2024-2029)

    Table 70. Novartis Corporation Information

    Table 71. Novartis Description and Business Overview

    Table 72. Novartis Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 73. Novartis Pegfilgrastim Biosimilar Product

    Table 74. Novartis Recent Developments/Updates

    Table 75. Mylan Corporation Information

    Table 76. Mylan Description and Business Overview

    Table 77. Mylan Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 78. Mylan Pegfilgrastim Biosimilar Product

    Table 79. Mylan Recent Developments/Updates

    Table 80. Coherus BioSciences Corporation Information

    Table 81. Coherus BioSciences Description and Business Overview

    Table 82. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 83. Coherus BioSciences Pegfilgrastim Biosimilar Product

    Table 84. Coherus BioSciences Recent Developments/Updates

    Table 85. Mundipharma International Corporation Information

    Table 86. Mundipharma International Description and Business Overview

    Table 87. Mundipharma International Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 88. Mundipharma International Pegfilgrastim Biosimilar Product

    Table 89. Mundipharma International Recent Developments/Updates

    Table 90. Biocon Corporation Information

    Table 91. Biocon Description and Business Overview

    Table 92. Biocon Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 93. Biocon Pegfilgrastim Biosimilar Product

    Table 94. Biocon Recent Developments/Updates

    Table 95. Intas Pharmaceuticals Corporation Information

    Table 96. Intas Pharmaceuticals Description and Business Overview

    Table 97. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 98. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product

    Table 99. Intas Pharmaceuticals Recent Developments/Updates

    Table 100. Pfizer Corporation Information

    Table 101. Pfizer Description and Business Overview

    Table 102. Pfizer Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 103. Pfizer Pegfilgrastim Biosimilar Product

    Table 104. Pfizer Recent Developments/Updates

    Table 105. Dr Reddy’s Laboratories Corporation Information

    Table 106. Dr Reddy’s Laboratories Description and Business Overview

    Table 107. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 108. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product

    Table 109. Dr Reddy’s Laboratories Recent Developments/Updates

    Table 110. Key Raw Materials Lists

    Table 111. Raw Materials Key Suppliers Lists

    Table 112. Pegfilgrastim Biosimilar Distributors List

    Table 113. Pegfilgrastim Biosimilar Customers List

    Table 114. Pegfilgrastim Biosimilar Market Trends

    Table 115. Pegfilgrastim Biosimilar Market Drivers

    Table 116. Pegfilgrastim Biosimilar Market Challenges

    Table 117. Pegfilgrastim Biosimilar Market Restraints

    Table 118. Research Programs/Design for This Report

    Table 119. Key Data Information from Secondary Sources

    Table 120. Key Data Information from Primary Sources

List of Figures

    Figure 1. Product Picture of Pegfilgrastim Biosimilar

    Figure 2. Global Pegfilgrastim Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

    Figure 3. Global Pegfilgrastim Biosimilar Market Share by Type in 2022 & 2029

    Figure 4. Chemotherapy Treatment Product Picture

    Figure 5. Transplantation Product Picture

    Figure 6. Global Pegfilgrastim Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Pegfilgrastim Biosimilar Market Share by Application in 2022 & 2029

    Figure 8. Hospital Pharmacies

    Figure 9. Mail-Order Pharmacies

    Figure 10. Retail Pharmacies

    Figure 11. Global Pegfilgrastim Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2029

    Figure 12. Global Pegfilgrastim Biosimilar Market Size (2018-2029) & (US$ Million)

    Figure 13. Global Pegfilgrastim Biosimilar Sales (2018-2029) & (K Units)

    Figure 14. Global Pegfilgrastim Biosimilar Average Price (US$/Unit) & (2018-2029)

    Figure 15. Pegfilgrastim Biosimilar Report Years Considered

    Figure 16. Pegfilgrastim Biosimilar Sales Share by Manufacturers in 2022

    Figure 17. Global Pegfilgrastim Biosimilar Revenue Share by Manufacturers in 2022

    Figure 18. The Global 5 and 10 Largest Pegfilgrastim Biosimilar Players: Market Share by Revenue in 2022

    Figure 19. Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

    Figure 20. Global Pegfilgrastim Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Figure 21. North America Pegfilgrastim Biosimilar Sales Market Share by Country (2018-2029)

    Figure 22. North America Pegfilgrastim Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 23. United States Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 24. Canada Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 25. Europe Pegfilgrastim Biosimilar Sales Market Share by Country (2018-2029)

    Figure 26. Europe Pegfilgrastim Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 27. Germany Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 28. France Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 29. U.K. Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 30. Italy Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 31. Russia Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 32. Asia Pacific Pegfilgrastim Biosimilar Sales Market Share by Region (2018-2029)

    Figure 33. Asia Pacific Pegfilgrastim Biosimilar Revenue Market Share by Region (2018-2029)

    Figure 34. China Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 35. Japan Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 36. South Korea Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 37. India Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 38. Australia Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 39. China Taiwan Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 40. Indonesia Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 41. Thailand Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 42. Malaysia Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 43. Latin America Pegfilgrastim Biosimilar Sales Market Share by Country (2018-2029)

    Figure 44. Latin America Pegfilgrastim Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 45. Mexico Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 46. Brazil Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 47. Argentina Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 48. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Country (2018-2029)

    Figure 49. Middle East & Africa Pegfilgrastim Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 50. Turkey Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 51. Saudi Arabia Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 52. UAE Pegfilgrastim Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 53. Global Sales Market Share of Pegfilgrastim Biosimilar by Type (2018-2029)

    Figure 54. Global Revenue Market Share of Pegfilgrastim Biosimilar by Type (2018-2029)

    Figure 55. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Type (2018-2029)

    Figure 56. Global Sales Market Share of Pegfilgrastim Biosimilar by Application (2018-2029)

    Figure 57. Global Revenue Market Share of Pegfilgrastim Biosimilar by Application (2018-2029)

    Figure 58. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Application (2018-2029)

    Figure 59. Pegfilgrastim Biosimilar Value Chain

    Figure 60. Pegfilgrastim Biosimilar Production Process

    Figure 61. Channels of Distribution (Direct Vs Distribution)

    Figure 62. Distributors Profiles

    Figure 63. Bottom-up and Top-down Approaches for This Report

    Figure 64. Data Triangulation

    Figure 65. Key Executives Interviewed